Clincosm LogoSign in Get a demo

Prevalence of Oral Mucosal Alterations in Mucocutaneous Ocular Disorders

Sponsor
Sherin Alaa Eldin Eisa Elsayed (Other)
Overall Status
Unknown status
CT.gov ID
NCT03679988
Collaborator
Cairo University (Other)
380
Enrollment
10
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The patients will be selected from the pool of the Clinics (Rheumatology, Ophthalmology and Dermatology) of Faculty of Medicine and (Diagnostic center and Oral Medicine) of Faculty of Dentistry -Cairo University. For each eligible participant, a full history will be obtained followed by thorough clinical examination.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    380 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Cross-Sectional
    Official Title:
    Prevalence of Oral Mucosal Alterations in a Sample of Egyptian Patients With Mucocutaneous Ocular Disorders: A Hospital Based Cross Sectional Study
    Anticipated Study Start Date :
    Oct 1, 2018
    Anticipated Primary Completion Date :
    May 30, 2019
    Anticipated Study Completion Date :
    Aug 1, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Identifying and recording oral mucosal alterations [10 min]

      clinical examination according to World Health Organization guidelines

    Secondary Outcome Measures

    1. Identifying the oral health-related quality of life: OHIP-14 [10 min]

      using Oral Health Impact Profile-14 (OHIP-14) Slade G. and Spencer A.: Development and evolution of the oral health impact profile. Community Dent Health, 11 (1): 3-11, 1994 Response categories for the five-point scale are: "Very often", "Fairly often", "Occasionally", "Hardly ever" and "Never".

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Adult patients diagnosed with one of the mucocutaneous disorder.

    • Patient who will agree to participate in the study.

    • Patients who will accept to sign the informed consent.

    Exclusion Criteria:
    • Patients not physically able to participate in survey or clinical oral examination.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Sherin Alaa Eldin Eisa Elsayed
    • Cairo University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sherin Alaa Eldin Eisa Elsayed, principle investigator , oral medicine department, Cairo University
    ClinicalTrials.gov Identifier:
    NCT03679988
    Other Study ID Numbers:
    • MCO oral alterations
    First Posted:
    Sep 21, 2018
    Last Update Posted:
    Sep 25, 2018
    Last Verified:
    Sep 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sherin Alaa Eldin Eisa Elsayed, principle investigator , oral medicine department, Cairo University
    oral health status
    oral findings
    oral manifestations
    patient with mucocutaneous ocular disorders
    mucocutaneous ocular disorders
    Additional relevant MeSH terms:
    Mouth Diseases

    Study Results

    No Results Posted as of Sep 25, 2018